WO2015171002A1 - Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine - Google Patents

Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine Download PDF

Info

Publication number
WO2015171002A1
WO2015171002A1 PCT/PT2014/000026 PT2014000026W WO2015171002A1 WO 2015171002 A1 WO2015171002 A1 WO 2015171002A1 PT 2014000026 W PT2014000026 W PT 2014000026W WO 2015171002 A1 WO2015171002 A1 WO 2015171002A1
Authority
WO
WIPO (PCT)
Prior art keywords
pirlindole
acid
pharmaceutically acceptable
acceptable salts
enantiomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PT2014/000026
Other languages
French (fr)
Inventor
Augusto Eugénio PARDAL FILIPE
Pedro Filipe EUFRÁSIO PEDROSO
Susana Marques ALMEIDA PECORELLI
Carlos Alberto Eufrásio CASIMIRO CAIXADO
Ana Sofia da Conceição LOPES
João Carlos Ramos DAMIL
Pedro Paulo de Lacerda E OLIVEIRA SANTOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tecnimede Sociedade Tecnico Medicinal SA
Original Assignee
Tecnimede Sociedade Tecnico Medicinal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HUE20198230A priority Critical patent/HUE068011T2/en
Priority to MA39450A priority patent/MA39450B2/en
Priority to SI201432095T priority patent/SI3831385T1/en
Priority to JP2016567531A priority patent/JP6400121B2/en
Priority to RS20240989A priority patent/RS65918B1/en
Priority to UAA201611335A priority patent/UA118587C2/en
Priority to HRP20241165TT priority patent/HRP20241165T1/en
Priority to SM20240359T priority patent/SMT202400359T1/en
Priority to PL20198230.3T priority patent/PL3831385T3/en
Priority to DK20198230.3T priority patent/DK3831385T3/en
Priority to NZ726127A priority patent/NZ726127A/en
Priority to US15/309,981 priority patent/US10226460B2/en
Priority to EP20198230.3A priority patent/EP3831385B1/en
Priority to CA2948595A priority patent/CA2948595C/en
Priority to KR1020167031370A priority patent/KR102276281B1/en
Priority to PCT/PT2014/000026 priority patent/WO2015171002A1/en
Priority to LTEP20198230.3T priority patent/LT3831385T/en
Application filed by Tecnimede Sociedade Tecnico Medicinal SA filed Critical Tecnimede Sociedade Tecnico Medicinal SA
Priority to EP14726441.0A priority patent/EP3139926A1/en
Priority to PT201982303T priority patent/PT3831385T/en
Priority to AU2014393487A priority patent/AU2014393487B2/en
Priority to MX2016014704A priority patent/MX373227B/en
Priority to FIEP20198230.3T priority patent/FI3831385T3/en
Priority to TN2016000495A priority patent/TN2016000495A1/en
Priority to RU2016148174A priority patent/RU2706688C2/en
Priority to ES20198230T priority patent/ES2988983T3/en
Priority to CN201480078725.0A priority patent/CN106413713B/en
Publication of WO2015171002A1 publication Critical patent/WO2015171002A1/en
Priority to IL248852A priority patent/IL248852B/en
Priority to ECIEPI201686196A priority patent/ECSP16086196A/en
Priority to SA516380258A priority patent/SA516380258B1/en
Priority to PH12016502235A priority patent/PH12016502235A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to novel pharmaceutically acceptable salts of enantiomerically pure (R) -pirlindole and (S) -pirlindole compounds useful in medicine.
  • Active pharmaceutical ingredients are frequently delivered to the patient in, for example, a solid-state as part of an approved dosage form. These active ingredients can exist in a variety of distinct solid forms, having each of them unique physiochemical properties that influence the bioavailability, e.g. dissolution and absorption of the drug. All of these technical characteristics are critical for development of the final drug product.
  • a pharmaceutical molecule to be "active" it has to reach it site of action in the body. Most often the molecules are not directly “bioavailable”, and are thus not directly absorbed in the body. In order to be absorbed, the molecules have to show adequate solubility and dissolution rates.
  • Dissolution of the molecule usually takes place in the stomach (for oral dosage forms), whereas the absorption takes place in the intestines.
  • the pH is quite low (varying from 1 to 5 depending on the individual), i.e. the initial dissolution takes place in a quite acidic environment.
  • many pharmaceutical products are either acids or bases it implies that the solubility/dissolution thereof is very dependant on the pH, so when evaluating the bioavailability of drugs pH dissolution values plays a crucial role.
  • [3, 2, 1-j , k] carbazole is a tetracyclic compound well known in medicine as being a reversible monoamine oxidase A inhibitor, useful as a medicament in the treatment of depression. Further, pirlindole has also been shown to be useful for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatisitis, as described in United States Patent Application US 2008/0254106.
  • Pirlindole pharmaceutically active forms include the mesylate and hydrochloride salts thereof.
  • the present invention therefore provides new, alternative and stable forms of pirlindole showing unexpectedly superior dissolution rates in acid environment, which result in increased absorption rates of the said active ingredient and thus are specially suitable to be used in medicine.
  • a first object of the invention are pharmaceutically acceptable salts of pirlindole ' enantiomers for use in medicine characterized in that the pirlindole enantiomers are enantiomerically pure (R) -pirlindole or (S) -pirlindole .
  • a still further object of the present invention are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that ⁇ the pharmaceutically acceptable salts of (R) -pirlindole or (S) -pirlindole are salts of organic, inorganic or optically active acids.
  • An additional object of the present application are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that these salts are salts of organic and inorganic acids of (R) -pirlindole or (S) -pirlindole, wherein the organic and inorganic acids are selected from the group consisting of: hydrochloric acid, hydrobromic acid ( HBR ) , sulfuric acid, phosphoric acid, citric acid, anhydrous citric acid, mandelic acid, succinic acid and methanesulfonic acid.
  • a further object of the present invention are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that the optically active acids forming the pharmaceutically acceptable salts of (R) -pirlindole or (S) -pirlindole are selected from the group consisting of: (S) -mandelic acid, ( R ) -mandelic acid, (R) - (+) -a-methoxy-a- trifluorophenyl acetic acid, (S) - (-) -a-methoxy-cx-trifluorophenyl acetic acid, (IS, 3R) -(-) -camphoric acid, (1R, 3S)- (+) -camphoric acid, L-(-) -malic acid, D- ⁇ +) -malic acid, or similarly well known in the art optically active acids.
  • An additional object of the present invention are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that the salts are selected from the group consisting of: (S) -pirlindole (R) -mandelate, ( R ) - pirlindole ( S ) -mandelate, (R) -pirlindole hydrobromide, ( S ) - pirlindole hydrobromide, ( S ) -pirlindole citrate, (R) -pirlindole citrate, (S) -pirlindole mesylate and (R) -pirlindole mesylate.
  • compositions for use in medicine comprising pharmaceutically acceptable salts of pirlindole enantiomers as previously defined with pharmaceutically acceptable carriers, vehicles or excipients.
  • a final object of the present invention are pharmaceutical compositions suitable for oral administration in the form of tablets, granules, fine granules, capsules, powders and pills.
  • Pirlindole has an asymmetric carbon atom, which implies that the molecule can exist in the form of two enantiomers, ( S ) - pirlindole and (R) -pirlindole .
  • the salt of the pirlindole racemic mixture, (rac)- pirlindole hydrochloride is to date the only salt form which is currently used in pharmaceutical dosage forms.
  • the said active pharmaceutical ingredient presents some difficulties concerning solubility, especially when administered in a subject who presents a highly acidic stomach pH of about 1-2, and as a consequence thereof, therapeutic treatments with such active ingredient are connected to poor absorption of the active ingredient and thus low bioavailability of the therapeutic agent.
  • bioavailability describes the fraction of an administered dose of unchanged drug substance that reaches systemic circulation after a particular route of administration.
  • Bioavailability is affected by first pass metabolism, solubility and instability of the drug substance.
  • When a drug substance is administered by intravenous route its bioavailability is 100%.
  • drug substance is administered via other routes (such as orally) , its bioavailability decreases due to incomplete absorption and first pass metabolism.
  • the low bioavailability is linked with a poor presence of the drug substance at the place of action (e.g., receptor, enzyme, ion channel) and therefore the pharmacological activity is compromised.
  • the inventors of the present invention have also found that the solubility of (rac) -pirlindole hydrochloride in 0.1 N HC1 is around 1.6 g/L which categorizes the product in that solvent media as slightly soluble and thus, with low bioavailability.
  • the term "pharmaceutically acceptable salt” refers to those salts of (R)- pirlindole and (S) -pirlindole which are, within the scope of sound medical evaluation, suitable for use in contact with the tissues and organs of humans and lower animals without displaying toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
  • the pirlindole molecule has a secondary amine group, which has basic character and thus can form acid addition salts, which may be pharmaceutically acceptable acids.
  • pharmaceutically acceptable salts according to the present invention include those pharmaceutically acceptable acid addition salts formed with organic and inorganic acids and those pharmaceutically acceptable salts formed with optically active acids.
  • Representative acid addition salts of (R) -pilindole and (S) -pirlindole include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, fumarate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate
  • Non-limiting examples of acids that can be used to form pharmaceutically acceptable acid addition salts with (R)- pilindole and (S) -pirlindole include inorganic acids such as hydrochloric acid, hydrobromic acid (HBR) , sulfuric acid and phosphoric acid and organic acids such as citric acid, anhydrous citric acid, mandelic acid, succinic acid and methanesulfonic acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid (HBR) , sulfuric acid and phosphoric acid
  • organic acids such as citric acid, anhydrous citric acid, mandelic acid, succinic acid and methanesulfonic acid.
  • Non-limiting examples of "optically active acids” that can be used to form pharmaceutically acceptable acid addition salts with (R) -pilindole and (S) -pirlindole include (S)-mandelic acid, (R)-mandelic acid, (R) - (+) - ⁇ -methoxy-a-trifluorophenyl acetic acid, (S) -(-) - ⁇ -methoxy-a-trifluorophenyl acetic acid, (1S,3R)- (-) -camphoric acid, (iR, 3S )-(+) -camphoric acid, L-(-) -malic acid, D- (+) -malic acid, or similarly well known in the art optically active acids.
  • the following assay shows the unexpected superior solubility rates of pharmaceutically acceptable salts of (R) - pirlindole and (S) -pirlindole according to the present invention versus the (rac) -pirlindole hydrochloride salt, known from the state of the art.
  • the Solubility test performed for showing the present invention' s advantages is well known in the state of the art and is based on the "Classical saturation shake-flask method", which comprises: Agitation at 37°C during 15h of supersaturated solution of the solid in HC1 (aq) 0,1N, followed by filtration, dilution with water and quantification by UV measurement at 267 nm wavelength.
  • the method used for obtaining the pharmaceutically acceptable salts of (R) -pirlindole and (S) -pirlindole contemplated in the present invention comprises crystallization of (rac) -pirlindole in the free base form with optically active acids in an organic solvent and, optionally its subsequent salification to form pharmaceutically acceptable salts with pharmaceutically acceptable acids.
  • the method comprises the following steps: i) Dissolving ( rac) -pirlindole hydrochloride in aqueous solvent, followed by a subsequent extraction with a chlorinated solvent and complete removal of the solvent to obtain (rac)- pirlindole in the free base form; ii) Dissolving the (rac) -pirlindole obtained in step i) in an organic solvent, followed by adding an optically active acid for resolution; iii) Stirring for 15 min to 2 h the suspension formed in ii) while diastereomeric salt precipitation occurs; iv) Filtering the obtained diastereomeric salt and purifying it by suspension in an organic solvent to obtain (S)- pirlindole or (R) ⁇ pirlindole enantiomer in the form of a pharmaceutically acceptable salt formed with the optically active acid; In addition to the detailed process steps, and where the products to be obtained are (S) -pirlindole or (R) - pirlindole enantioraer as
  • aqueous solvent refers, for example, to deionized water.
  • organic solvent refers to solvents commonly used in organic chemistry or mixtures thereof in any proportions.
  • Non-limiting examples of organic solvents used in steps ii) and iv) of the process of the present invention are selected from the group consisting of: methanol, ethanol, propanol, 1- butanol, 2-butanol, tert-butyl alcohol, 2-butanone, acetone, ethyl methyl ketone, methyl isobutyl ketone, dimethyl sulfoxide, 1, 2-dichloroethane, diethyl ether, dimethyl ether, dimethylformamide, methyl tert-butyl ether, 2-propanol, pyridine, toluene, xylene and the like, and mixtures thereof in any proportion.
  • chlorinated solvent means chloroform, dichloromethane, methylene chloride, trichloromethane or carbon tetrachloride, or mixtures thereof in any proportions.
  • chlorinated solvent means chloroform, dichloromethane, methylene chloride, trichloromethane or carbon tetrachloride, or mixtures thereof in any proportions.
  • it is considered as enantiomerically pure when enantiomeric purity as calculated by chiral chromatography or specific optical rotation is equal to or greater than 97%.
  • the present invention further provides new pharmaceutical dosage forms comprising new pharmaceutically acceptable salts of (R) -pudindolo and new pharmaceutically acceptable salts of ⁇ (S) - pirlindole according to the present invention together with pharmaceutically acceptable carriers, vehicles and/or suitable excipients.
  • pharmaceutically acceptable carrier means a solid, semi-solid or inert fluid excipient, filler, encapsulating or formulation aiding material of any kind already known by one skilled in the art.
  • compositions of the present invention can be formulated to be administered to humans and other mammals orally, (in liquid or solid forms) rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (in the form of powders, ointments or drops) , buccally or in the form of an oral or nasal spray.
  • parenterally refers to modes of administration, including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intra-articular injection and infusion.
  • compositions for parenteral injection include aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, pharmaceutically acceptable sterile or non-sterile, and powders for reconstitution in sterile injectable solutions or dispersions.
  • the compounds of the invention ' can be embedded in extended controlled release or directed administration systems, such as polymeric matrices, liposomes and microspheres.
  • the pharmaceutical composition of the present invention is preferably a solid composition for oral administration, and specific examples thereof include tablets, granules, fine granules, capsules, powders, and pills.
  • the solid oral composition of the present invention can have an excipient, a binder, a lubricant and the like added thereto, in addition to the pharmaceutically acceptable salt of (R) -pirlindole or (S) -pirlindole, and can be formulated into the respective forms.
  • excipients that may be used include lactose, corn starch, crystalline cellulose, sucrose, glucose, mannitol, sorbitol, and calcium carbonate.
  • the binder include hydroxypropyl cellulose, hydroxyethyl cellulose, hypromellose, hydroxyethylethyl cellulose, hydroxyethylmethyl cellulose, polyvinylpyrrolidone, and polyvinyl alcohol.
  • the lubricant include magnesium stearate, stearic acid, palmitic acid, calcium stearate, and talc.
  • the tablets may be produced by uniformly mixing the various components described above, and producing the tablets by a general-purpose wet granulation compression method, a direct powder compression method, or the like.
  • the tablets thus obtained may be further subjected to film coating, sugar coating, sustained release coating, or the like, such as, embedded in extended controlled release or directed administration systems, such as polymeric matrices, liposomes and microspheres.
  • examples of the possible coating agent include hypromellose, hydroxypropyl cellulose, polyvinyl alcohol, titanium oxide, talc, polyethylene glycol, triethyl citrate, stearic acid, hydrated silicon dioxide, and light silicic anhydride.
  • examples of the sugar coating include gum arable, purified gelatin, gelatin, purified sucrose, sucrose, precipitated calcium carbonate, talc, and calcium dihydrogen phosphate hydrate.
  • examples of the sustained release coating agent include methacrylic acid copolymer LD, ethyl cellulose, aminoalkyl methacrylate copolymer RS, and hypromellose.
  • dosage of the active ingredients of the present invention administered to an individual will be dependent upon the response desired and may be dependent upon the subject to be treated, its age, health, weight, frequency of treatment etc.
  • dosage levels contemplated according to the present invention comprise, from 0.1 to 10 mg/kg for oral administration, from 0.01 to 10 mg/kg for intravenous administration.
  • the precipitated product is filtered, washed with 2x100 mL of acetone and dried under vacuum at 35°C-45°C.
  • Example 2 The product obtained in Example 1 (10 g, 0.027 mole) was dissolved in 550 ml of deionized water. The aqueous phase was extracted with 3 x 300 ml of chloroform. The combined organic phases were dried over sodium sulfate, evaporated to dryness under vacuum and 200 ml of acetone were added.
  • the dried precipitated product is filtered, washed with 2x10 ml of acetone and dried under vacuum at 35°C-45°C.
  • Example 2 The product obtained in Example 1 (10 g, 0.027 mole) was dissolved in 550 ml of deionized water. The aqueous phase was extracted with 3 x 300 ml of trichloroethane . The combined organic phases were dried over sodium sulfate, evaporated to dryness under vacuum and 200 ml of acetone were added.
  • Lactose monohydrate 99 to 1 % The manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.
  • the manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.
  • the manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.
  • the manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides pharmaceutically acceptable salts of enantiomerically pure(R)-pirlindole and (S)-pirlindole compounds having an increased bioavailability profile for use in medicine.

Description

DESCRIPTION
PHARMACEUTICALLY ACCEPTABLE SALTS OF PIRLINDOLE ENANTIOMERS FOR USE IN MEDICINE
The present invention relates to novel pharmaceutically acceptable salts of enantiomerically pure (R) -pirlindole and (S) -pirlindole compounds useful in medicine.
BACKGROUND
Active pharmaceutical ingredients are frequently delivered to the patient in, for example, a solid-state as part of an approved dosage form. These active ingredients can exist in a variety of distinct solid forms, having each of them unique physiochemical properties that influence the bioavailability, e.g. dissolution and absorption of the drug. All of these technical characteristics are critical for development of the final drug product.
In particular, for a pharmaceutical molecule to be "active" it has to reach it site of action in the body. Most often the molecules are not directly "bioavailable", and are thus not directly absorbed in the body. In order to be absorbed, the molecules have to show adequate solubility and dissolution rates.
Dissolution of the molecule usually takes place in the stomach (for oral dosage forms), whereas the absorption takes place in the intestines. In the stomach the pH is quite low (varying from 1 to 5 depending on the individual), i.e. the initial dissolution takes place in a quite acidic environment. As many pharmaceutical products are either acids or bases it implies that the solubility/dissolution thereof is very dependant on the pH, so when evaluating the bioavailability of drugs pH dissolution values plays a crucial role.
Pirlindole, 2, 3, 3a, 4, 5, 6-hexahydro-lH-8-methyl-pyrazine
[3, 2, 1-j , k] carbazole, is a tetracyclic compound well known in medicine as being a reversible monoamine oxidase A inhibitor, useful as a medicament in the treatment of depression. Further, pirlindole has also been shown to be useful for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatisitis, as described in United States Patent Application US 2008/0254106.
Pirlindole pharmaceutically active forms include the mesylate and hydrochloride salts thereof.
However, therapeutic treatment methods with pirlindole have shown ; that there still exists field of improvement as regards the provision of alternative forms of the parent compound pirlindole which show an improved dissolution rate and solubility rate adequate for drug developing purposes.
The present invention therefore provides new, alternative and stable forms of pirlindole showing unexpectedly superior dissolution rates in acid environment, which result in increased absorption rates of the said active ingredient and thus are specially suitable to be used in medicine.
BRIEF DESCRIPTION OF THE INVENTION
The inventors of the present invention have found that specific salts of both enantiomers, (S) -pirlindole and (R) - pirlindole show unexpected superior solubility rates in an acidic environment, thus providing for unexpected superior dissolution profiles of the active ingredient in the stomach and as a consequence thereof superior adsorption in the intestines.
It is therefore an object of the present invention the provision of pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine.
Therefore, a first object of the invention are pharmaceutically acceptable salts of pirlindole ' enantiomers for use in medicine characterized in that the pirlindole enantiomers are enantiomerically pure (R) -pirlindole or (S) -pirlindole .
A still further object of the present invention are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that · the pharmaceutically acceptable salts of (R) -pirlindole or (S) -pirlindole are salts of organic, inorganic or optically active acids. An additional object of the present application are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that these salts are salts of organic and inorganic acids of (R) -pirlindole or (S) -pirlindole, wherein the organic and inorganic acids are selected from the group consisting of: hydrochloric acid, hydrobromic acid ( HBR ) , sulfuric acid, phosphoric acid, citric acid, anhydrous citric acid, mandelic acid, succinic acid and methanesulfonic acid.
A further object of the present invention are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that the optically active acids forming the pharmaceutically acceptable salts of (R) -pirlindole or (S) -pirlindole are selected from the group consisting of: (S) -mandelic acid, ( R ) -mandelic acid, (R) - (+) -a-methoxy-a- trifluorophenyl acetic acid, (S) - (-) -a-methoxy-cx-trifluorophenyl acetic acid, (IS, 3R) -(-) -camphoric acid, (1R, 3S)- (+) -camphoric acid, L-(-) -malic acid, D- {+) -malic acid, or similarly well known in the art optically active acids.
An additional object of the present invention are pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine characterized in that the salts are selected from the group consisting of: (S) -pirlindole (R) -mandelate, ( R ) - pirlindole ( S ) -mandelate, (R) -pirlindole hydrobromide, ( S ) - pirlindole hydrobromide, ( S ) -pirlindole citrate, (R) -pirlindole citrate, (S) -pirlindole mesylate and (R) -pirlindole mesylate.
A still further object of the present invention are pharmaceutical compositions for use in medicine comprising pharmaceutically acceptable salts of pirlindole enantiomers as previously defined with pharmaceutically acceptable carriers, vehicles or excipients.
A final object of the present invention are pharmaceutical compositions suitable for oral administration in the form of tablets, granules, fine granules, capsules, powders and pills.
DESCRIPTION OF THE INVENTION
Pirlindole has an asymmetric carbon atom, which implies that the molecule can exist in the form of two enantiomers, ( S ) - pirlindole and (R) -pirlindole .
To date, however, there is no pharmaceutical product for any of those enantiomers, either already approved or awaiting approval, and only the use of the racemate form, as a salt of hydrochloric acid, is known in medicine. The inventors of the present invention have found that specific salts of both enantiomers, ( S ) -pirlindole and (R) - pirlindole show unexpected superior solubility rates in an acidic environment, thus providing for unexpected superior dissolution profiles of the active ingredient in the stomach, superior adsorption in the intestines and as a consequence thereof an unexpectedly superior bioavailability profile of the active ingredient.
These salts of (S) -pirlindole and (R)- pirlindole are new compounds, not disclosed before in the prior art, as according to the available prior art, no suitable method existed for providing the pharmaceutically acceptable salts of these optically active compounds.
To this regard, the publication Chirality 11:261-266 (1999), fails to obtain pharmaceutically acceptable salts of the enantiomers of pirlindole by selective crystallization with optically active acids on an industrial scale. The document describes the use of the derivatization technique in conjunction with preparative chromatography.
However, for the purpose of the present invention, the inventors of the present application were able to obtain enantiomerically pure (R) -pirlindole and (S) -pirlindole by crystallization with optically active acids, in the form of pharmaceutically acceptable salts.
The obtention of the pharmaceutically acceptable salts of the enantiomers of pirlindole, led the present inventors to the findings on which the present application is based.
The salt of the pirlindole racemic mixture, (rac)- pirlindole hydrochloride, is to date the only salt form which is currently used in pharmaceutical dosage forms. To this regard it is well known that the said active pharmaceutical ingredient presents some difficulties concerning solubility, especially when administered in a subject who presents a highly acidic stomach pH of about 1-2, and as a consequence thereof, therapeutic treatments with such active ingredient are connected to poor absorption of the active ingredient and thus low bioavailability of the therapeutic agent.
To this regard, bioavailability describes the fraction of an administered dose of unchanged drug substance that reaches systemic circulation after a particular route of administration. Bioavailability is affected by first pass metabolism, solubility and instability of the drug substance. When a drug substance is administered by intravenous route its bioavailability is 100%. However, when drug substance is administered via other routes (such as orally) , its bioavailability decreases due to incomplete absorption and first pass metabolism. The low bioavailability is linked with a poor presence of the drug substance at the place of action (e.g., receptor, enzyme, ion channel) and therefore the pharmacological activity is compromised.
The inventors of the present invention have also found that the solubility of (rac) -pirlindole hydrochloride in 0.1 N HC1 is around 1.6 g/L which categorizes the product in that solvent media as slightly soluble and thus, with low bioavailability.
For the purpose of the present invention, the term "pharmaceutically acceptable salt" refers to those salts of (R)- pirlindole and (S) -pirlindole which are, within the scope of sound medical evaluation, suitable for use in contact with the tissues and organs of humans and lower animals without displaying toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio. Further, the pirlindole molecule has a secondary amine group, which has basic character and thus can form acid addition salts, which may be pharmaceutically acceptable acids.
Therefore, pharmaceutically acceptable salts according to the present invention include those pharmaceutically acceptable acid addition salts formed with organic and inorganic acids and those pharmaceutically acceptable salts formed with optically active acids.
Representative acid addition salts of (R) -pilindole and (S) -pirlindole include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, fumarate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate
(isethionate) , lactate, maleate, methanesulfonate, nicotinate,
2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate,
3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate , glutamate, bicarbonate, p- toluenesulfonate and undecanoate.
Non-limiting examples of acids that can be used to form pharmaceutically acceptable acid addition salts with (R)- pilindole and (S) -pirlindole include inorganic acids such as hydrochloric acid, hydrobromic acid (HBR) , sulfuric acid and phosphoric acid and organic acids such as citric acid, anhydrous citric acid, mandelic acid, succinic acid and methanesulfonic acid. Non-limiting examples of "optically active acids" that can be used to form pharmaceutically acceptable acid addition salts with (R) -pilindole and (S) -pirlindole include (S)-mandelic acid, (R)-mandelic acid, (R) - (+) -α-methoxy-a-trifluorophenyl acetic acid, (S) -(-) -α-methoxy-a-trifluorophenyl acetic acid, (1S,3R)- (-) -camphoric acid, (iR, 3S )-(+) -camphoric acid, L-(-) -malic acid, D- (+) -malic acid, or similarly well known in the art optically active acids.
Pharmaceutically acceptable salts of pirlindole enantiomers according to the present invention include:
(S) -pirlindole (R) -mandelate, (R) -pirlindole (S)- mandelate, (R) -pirlindole hydrobromide, :(S) -pirlindole hydrobromide, (S) -pirlindole citrate, (R) -pirlindole citrate, (S) -pirlindole mesylate and (R) -pirlindole mesylate, (S) - pirlindole (R) - (+) -a-methoxy-a-trifluorophenylacetate, (S)- pirlindole benzenesulfonate, (R) -pirlindole p- toluenesulfonate, (S) -pirlindole bisulfate, (R) -pirlindole oxalate, (R) -pirlindole maleate, (S) -pirlindole acetate, (S)- pirlindole glutamate, (S) -pirlindole lactate, (R) -pirlindole adipate, (R) -pirlindole benzoate and (S) -pirlindole malate.
As said before, surprisingly the inventors of the present invention have found that pharmaceutically acceptable salts of pirlindole enantiomers, ( (R) -pirlindole and (S) -pirlindole) show unexpectedly superior solubility rates in a highly acidic pH, and are thus especially suitable for use in medicine.
The following assay shows the unexpected superior solubility rates of pharmaceutically acceptable salts of (R) - pirlindole and (S) -pirlindole according to the present invention versus the (rac) -pirlindole hydrochloride salt, known from the state of the art.
The Solubility test performed for showing the present invention' s advantages is well known in the state of the art and is based on the "Classical saturation shake-flask method", which comprises: Agitation at 37°C during 15h of supersaturated solution of the solid in HC1 (aq) 0,1N, followed by filtration, dilution with water and quantification by UV measurement at 267 nm wavelength.
The results obtained are shown in the following Table 1. Table 1: Data solubility in 0.1 N HC1
Figure imgf000008_0001
From the data presented in the Table 1, one can easily conclude that the solubility of the new salts of the enantiomers of pirlindole is 3 to 4 times higher than that of (rac) -pirlindole hydrochloride, which is a very significant and surprising result.
The method used for obtaining the pharmaceutically acceptable salts of (R) -pirlindole and (S) -pirlindole contemplated in the present invention comprises crystallization of (rac) -pirlindole in the free base form with optically active acids in an organic solvent and, optionally its subsequent salification to form pharmaceutically acceptable salts with pharmaceutically acceptable acids.
The method comprises the following steps: i) Dissolving ( rac) -pirlindole hydrochloride in aqueous solvent, followed by a subsequent extraction with a chlorinated solvent and complete removal of the solvent to obtain (rac)- pirlindole in the free base form; ii) Dissolving the (rac) -pirlindole obtained in step i) in an organic solvent, followed by adding an optically active acid for resolution; iii) Stirring for 15 min to 2 h the suspension formed in ii) while diastereomeric salt precipitation occurs; iv) Filtering the obtained diastereomeric salt and purifying it by suspension in an organic solvent to obtain (S)- pirlindole or (R)~ pirlindole enantiomer in the form of a pharmaceutically acceptable salt formed with the optically active acid; In addition to the detailed process steps, and where the products to be obtained are (S) -pirlindole or (R) - pirlindole enantioraer as a pharmaceutically acceptable acid addition salt with suitable organic and inorganic acids, the said process contemplates optionally the following steps v) Obtaining enantiomerically pure (S) -pirlindole and/or (R)- pirlindole as a free base by dissolution of the product obtained in step iv) in an aqueous solvent, subsequent extraction with chlorinated solvent and complete removal of the solvent; and vi) Obtaining S) -pirlindole or (R) - pirlindole in the form of pharmaceutically acceptable acid addition salts by salification of the enantiomerically pure (S) -pirlindole and/or (R) - pirlindole in the form of a free base obtained in step v) with a pharmaceutically acceptable acid to form a pharmaceutically acceptable acid addition salt of S) -pirlindole or (R) - pirlindole enantiomer.
For the purposes of the present invention the term "aqueous solvent" refers, for example, to deionized water.
For purposes of this invention the term "organic solvent" refers to solvents commonly used in organic chemistry or mixtures thereof in any proportions.
Non-limiting examples of organic solvents used in steps ii) and iv) of the process of the present invention are selected from the group consisting of: methanol, ethanol, propanol, 1- butanol, 2-butanol, tert-butyl alcohol, 2-butanone, acetone, ethyl methyl ketone, methyl isobutyl ketone, dimethyl sulfoxide, 1, 2-dichloroethane, diethyl ether, dimethyl ether, dimethylformamide, methyl tert-butyl ether, 2-propanol, pyridine, toluene, xylene and the like, and mixtures thereof in any proportion.
Preferred are the following solvents: ethanol, methanol, 1- butanol, 2-butanol, tert-butyl alcohol, acetone, methyl ethyl ketone and isopropanol as well as mixtures thereof in any proportions, such as isopropanol/acetone (1:1), ethanol/acetone (1:1), ethanol/methyl isobutyl ketone (1:1) and ethanol/1- butanol (1:4) .
For purposes of this invention the term "chlorinated solvent" means chloroform, dichloromethane, methylene chloride, trichloromethane or carbon tetrachloride, or mixtures thereof in any proportions. For purposes of this invention, it is considered as enantiomerically pure when enantiomeric purity as calculated by chiral chromatography or specific optical rotation is equal to or greater than 97%.
The present invention further provides new pharmaceutical dosage forms comprising new pharmaceutically acceptable salts of (R) -piriindolo and new pharmaceutically acceptable salts of ~ (S) - pirlindole according to the present invention together with pharmaceutically acceptable carriers, vehicles and/or suitable excipients.
The term "pharmaceutically acceptable carrier, vehicle or excipient" as used here, means a solid, semi-solid or inert fluid excipient, filler, encapsulating or formulation aiding material of any kind already known by one skilled in the art.
Pharmaceutical compositions of the present invention can be formulated to be administered to humans and other mammals orally, (in liquid or solid forms) rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (in the form of powders, ointments or drops) , buccally or in the form of an oral or nasal spray. The term "parenterally", as used here, refers to modes of administration, including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intra-articular injection and infusion.
Pharmaceutical compositions for parenteral injection include aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, pharmaceutically acceptable sterile or non-sterile, and powders for reconstitution in sterile injectable solutions or dispersions.
If it is required, and for a more effective distribution, the compounds of the invention ' can be embedded in extended controlled release or directed administration systems, such as polymeric matrices, liposomes and microspheres.
The pharmaceutical composition of the present invention is preferably a solid composition for oral administration, and specific examples thereof include tablets, granules, fine granules, capsules, powders, and pills.
The solid oral composition of the present invention can have an excipient, a binder, a lubricant and the like added thereto, in addition to the pharmaceutically acceptable salt of (R) -pirlindole or (S) -pirlindole, and can be formulated into the respective forms. Examples of excipients that may be used include lactose, corn starch, crystalline cellulose, sucrose, glucose, mannitol, sorbitol, and calcium carbonate. Examples of the binder include hydroxypropyl cellulose, hydroxyethyl cellulose, hypromellose, hydroxyethylethyl cellulose, hydroxyethylmethyl cellulose, polyvinylpyrrolidone, and polyvinyl alcohol. Examples of the lubricant include magnesium stearate, stearic acid, palmitic acid, calcium stearate, and talc.
Such formulations are described in detail in a number of sources which are well known and readily available to those skilled in the art. For example, Remington's The Science and Practice of Pharmacy, edited by Allen, Loyd V., Jr, 22nd edition, describe the making of formulations which can be used in connection with the subject invention.
Further, there are no particular limitations on the method for preparing the solid pharmaceutical compositions of the present invention, but for example, in the case of tablets, the tablets may be produced by uniformly mixing the various components described above, and producing the tablets by a general-purpose wet granulation compression method, a direct powder compression method, or the like. Furthermore, the tablets thus obtained may be further subjected to film coating, sugar coating, sustained release coating, or the like, such as, embedded in extended controlled release or directed administration systems, such as polymeric matrices, liposomes and microspheres. In this case, examples of the possible coating agent include hypromellose, hydroxypropyl cellulose, polyvinyl alcohol, titanium oxide, talc, polyethylene glycol, triethyl citrate, stearic acid, hydrated silicon dioxide, and light silicic anhydride. Examples of the sugar coating include gum arable, purified gelatin, gelatin, purified sucrose, sucrose, precipitated calcium carbonate, talc, and calcium dihydrogen phosphate hydrate. Examples of the sustained release coating agent include methacrylic acid copolymer LD, ethyl cellulose, aminoalkyl methacrylate copolymer RS, and hypromellose.
The dosage of the active ingredients of the present invention administered to an individual will be dependent upon the response desired and may be dependent upon the subject to be treated, its age, health, weight, frequency of treatment etc. For example, dosage levels contemplated according to the present invention comprise, from 0.1 to 10 mg/kg for oral administration, from 0.01 to 10 mg/kg for intravenous administration. EXAMPLES
The examples below are intended to illustrate the invention and should not be construed as limiting thereof.
EXAMPLE 1
(R) -pirlindole (S) -mandelate
100 g (0.38 mole) of (R, S) -pirlindole hydrochloride are dissolved in 16 L deionized water at room temperature. To the solution are added 42.4 g (0.4 mole) of anhydrous sodium carbonate and stir for l-2h.
The above solution is extracted with 3x4 L of dichloromethane and the combined organic phases are dried over sodium sulfate and evaporated under vacuum to dryness.
To the concentrate was added 2 L of acetone.
To the above solution is added, under stirring, a solution of 27.6 g (0.18 mole) of (S)-mandelic acid in 150 ml of acetone.
The precipitated product is filtered, washed with 2x100 mL of acetone and dried under vacuum at 35°C-45°C.
The above product is suspended in ethanol (250 mL) and is subsequently filtered and dried under vacuum at 35°C-45°C, yielding 48.5 g (0.13 mole) of (R) -pirlindole (S) -mandelate, (yield = 68%). Chiral HPLC (enantiomeric purity = 98.2%).
EXAMPLE 2
(S) -pirlindole (R) -mandelate
Using the same procedure as in Example 1, starting from 100 g (0.38 mole) of (R, S) -pirlindole hydrochloride and using 27.6 g (0.18 mole) of (R)-mandelic acid, yielded 45.6 g (0.12 mole) of (S) -pirlindole (R) -mandelate (yield = 63%) . Chiral HPLC (enantiomeric purity = 98.7%).
EXAMPLE 3
(S) -pirlindole (R) -mandelate
Using the same procedure as in Example 1, except that a mixture of isopropanol/acetone (1:1) is used as the organic solvent, starting from 10 g (0.038 mole) of (R, S ) -pirlindole hydrochloride and using 2.8 g (0.018 mole) of (R)-mandelic acid, yielded 4,1 g (0.011 mole) of (S) -pirlindole (R) -mandelate
(yield = 57.9%). Chiral HPLC (enantiomeric purity = 98.1%). EXAMPLE 4
(S) -pirlindole (R) - (+) -a-methoxy-ot-trifluorophenyl acetate
Using the same procedure as in Example 1, except that a mixture of ethanol/acetone (1:1) was used as the organic solvent and as optically active acid, (R) - (+) -a-methoxy- - trifluorophenylacetic acid (8.3 g) (0.018 mole) was used, starting from 10 g (0.038 mole) of (R, S) -pirlindole
hydrochloride, yieled 4.8 g (0.010 mole) of (S) -pirlindole (R) - (+) -a-methoxy-a-trifluorophenylacetate (yield = 52.6% ) . Chiral HPLC (enantiomeric purity = 97.7%).
EXAMPLE 5
(R) -Pirlindole hydrobromide
The product obtained in Example 1 (10 g, 0.027 mole) was dissolved in 550 ml of deionized water. The aqueous phase was extracted with 3 x 300 ml of chloroform. The combined organic phases were dried over sodium sulfate, evaporated to dryness under vacuum and 200 ml of acetone were added.
To the above solution, under stirring, a solution of 6 ml of HBr (48% aqueous solution) (0.04 mole) was added.
The dried precipitated product is filtered, washed with 2x10 ml of acetone and dried under vacuum at 35°C-45°C.
The above product was suspended in ethanol/methyl isobutyl ketone (1:1) (250 mL) and was subsequently filtered and dried under vacuum at 35°C-45°C, yielding 6.5 g (0.021 mole) of (R) - pirlindole hydrobromide (yield = 77.8% ). Chiral HPLC (enantiomeric purity = 97.9%).
EXAMPLE 6
(R) -Pirlindole citrate
The product obtained in Example 1 (10 g, 0.027 mole) was dissolved in 550 ml of deionized water. The aqueous phase was extracted with 3 x 300 ml of trichloroethane . The combined organic phases were dried over sodium sulfate, evaporated to dryness under vacuum and 200 ml of acetone were added.
To the above solution, under stirring 7.7 g of anhydrous citric acid (0.04 mole) were added.
The dried precipitated product was filtered, washed with 2x10 ml of acetone and dried under vacuum at 35°C-45°C. The above product was suspended in etanol/l-butanol (1:4) (250 mL) and was subsequently filtered and dried under vacuum at 35°C-45°C, yielding 9.2 g (0.020 mole) of of (R) -pirlindole citrate (yield = 74.1% ) . Chiral HPLC (enantiomeric purity = 97.6%).
EXAMPLE 7
(R)^-Pirlindole mesylate
Starting from 10 g of (R) -pirlindole (S) -mandelate obtained in Example 1 and following the procedure described in Example 5 using methanesulfonic acid as pharmaceutical acceptable acid, ,
7.4 g (0.023 mole) of (R) -pirlindole mesylate were obtained (yield = 85.2% ). Chiral HPLC (enantiomeric purity = 98.0%).
EXAMPLE 8
(S) -pirlindole hydrobromide
Starting from 10 g of (S) -pirlindole (R) -mandelate obtained in Example 2 using hydrobromic acid as pharmaceutical acceptable acid, and following the procedure described in Example 6, 7.4 g (0.024 mole) of (S) -pirlindole hydrobromide were obtained (yield = 88.9%) . Chiral HPLC (enantiomeric purity = 98.2%).
EXAMPLE 9
(S) -pirlindole mesylate
Starting from 10 g of (S) -pirlindole (R) -mandelate obtained in Example 2 and following the procedure described in Example 6 using methanesulfonic acid as pharmaceutical acceptable acid, 6.8 g (0.021 mole) of (S) -pirlindole mesylate were obtained (yield = 77.8%) . Chiral HPLC (enantiomeric purity = 98.0%).
EXAMPLE 10
(S) -Pirlindole citrate
Starting from 10 g of (R) -mandelate of (S ) -pirlindole obtained in Example 2 and following the procedure described in Example 6 using citric acid as pharmaceutical acceptable acid ,
9.5 g (0.021 mole) of (R) -pirlindole citrate were obtained (yield = 77.8% ). Chiral HPLC (enantiomeric purity = 98.5%).
EXAMPLE 11
Pharmaceutical compositions
Sachets of (S ) -Pirlindole mesylate (amounts are given in % weight with respect to the total composition)
(S) -Pirlindole mesylate .... 1 to 99 %
Lactose monohydrate 99 to 1 % The manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.
Sachets of (R) -Pirlindole mesylate (amounts are given in % weight with respect to the total composition)
(R) -Pirlindole mesylate .... 1,5 to 98,5 %
Lactose monohydrate 98,5 to 1,5 %
The manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.
Sachets of (S) -Pirlindole (R) -mandelate (amounts are given in % weight with respect to the total composition)
(S) -Pirlindole (R) -mandelate .... 1 to 99 %
Lactose monohydrate 99 to 1 %
The manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.
Sachets of (R) -Pirlindole (S) -mandelate (amounts are given in % weight with respect to the total composition)
(R) -Pirlindole (S) -mandelate .... 2 to 98 %
Lactose monohydrate 98 to 2 %
The manufacture of the sachets includes mixing all components, passing them through a sieve and, filling and packaging the mixture into a sachet.
Lisbon, May 8, 2014.

Claims

1. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine.
2. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine according to claim 1 characterized -in- that the pirlindole enantiomers are enantiomerically pure(R)- pirlindole or (S) -pirlindole .
3. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine according to claims 1 and 2, characterized in that the pharmaceutically acceptable salts of (R) -pirlindole or (S ) -pirlindole are salts of organic, inorganic or optically active acids.
4. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine according to claims 1 to 3, characterized in that the organic and inorganic acids forming the pharmaceutically acceptable salts of (R) -pirlindole or (S)- pirlindole are selected from the group consisting of: hydrochloric acid, hydrobromic acid (HBR) , sulfuric acid, phosphoric acid, citric acid, anhydrous citric acid, mandelic acid, succinic acid and methanesulfonic acid.
5. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine according to claims 1 to 3, characterized in that the optically active acids forming the pharmaceutically acceptable salts of (R) -pirlindole or (S) -pirlindole are selected from the group consisting of: (S) -mandelic acid, (R) - mandelic acid, (R) - (+) - -methoxy-a-trifluorophenylacetic acid, (S) - (-) - -methoxy- -trifluorophenylacetic acid, (lS,3R)-(-)- camphoric acid, (1R, 3S) -(+) -camphoric acid, L-(-) -malic acid, D-(+) -malic acid, or similarly well known in the art optically active acids.
6. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine according to any previous claim characterized in that the salts are selected from the group consisting of: (S) -pirlindole (R) -mandelate, (R) -pirlindole (S)- mandelate, (R) -pirlindole hydrobromide, (S) -pirlindole hydrobromide, (S) -pirlindole citrate, (R) -pirlindole citrate, (S) -pirlindole mesylate and (R) -pirlindole mesylate.
7. Pharmaceutical composition for use in medicine comprising pharmaceutically acceptable, salts of pirlindole enantiomers according to any previous claim together with pharmaceutically acceptable carriers, vehicles or excipients.
8. Pharmaceutical composition according to claim 7 suitable for oral administration in the form of tablets, granules, fine granules, capsules, powders and pills.
Lisbon, May 8, 2014.
PCT/PT2014/000026 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine Ceased WO2015171002A1 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
LTEP20198230.3T LT3831385T (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
SI201432095T SI3831385T1 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
JP2016567531A JP6400121B2 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for medical use
RS20240989A RS65918B1 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
UAA201611335A UA118587C2 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
HRP20241165TT HRP20241165T1 (en) 2014-05-09 2014-05-09 MANDELATE SALTS OF PIRLINDOLE ENANTIOMERES FOR MEDICAL USE
SM20240359T SMT202400359T1 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
PL20198230.3T PL3831385T3 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
DK20198230.3T DK3831385T3 (en) 2014-05-09 2014-05-09 MANDELATE SALTS OF PIRLINDOLE ENANTIOMER FOR USE IN MEDICINE
EP14726441.0A EP3139926A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
US15/309,981 US10226460B2 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
EP20198230.3A EP3831385B1 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
CA2948595A CA2948595C (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
KR1020167031370A KR102276281B1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
PCT/PT2014/000026 WO2015171002A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
HUE20198230A HUE068011T2 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
MA39450A MA39450B2 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of enantiomers of pirlindole for use in medicine
NZ726127A NZ726127A (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
PT201982303T PT3831385T (en) 2014-05-09 2014-05-09 MANDELATE SALTS OF PYRLINDOLE ENANTIOMERS FOR USE IN MEDICINE
AU2014393487A AU2014393487B2 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
MX2016014704A MX373227B (en) 2014-05-09 2014-05-09 PHARMACEUTICALLY ACCEPTABLE SALTS OF PIRLINDOL ENANTIOMERS FOR MEDICAL USE.
FIEP20198230.3T FI3831385T3 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
TN2016000495A TN2016000495A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine.
RU2016148174A RU2706688C2 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pyrilindole enantiomers for use in medicine
ES20198230T ES2988983T3 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine
CN201480078725.0A CN106413713B (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use as medicaments
IL248852A IL248852B (en) 2014-05-09 2016-11-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
ECIEPI201686196A ECSP16086196A (en) 2014-05-09 2016-11-09 PHARMACEUTICALLY ACCEPTABLE SALTS OF PIRLINDOLE ENANTIOMERS FOR USE IN MEDICINE
SA516380258A SA516380258B1 (en) 2014-05-09 2016-11-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
PH12016502235A PH12016502235A1 (en) 2014-05-09 2016-11-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000026 WO2015171002A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine

Publications (1)

Publication Number Publication Date
WO2015171002A1 true WO2015171002A1 (en) 2015-11-12

Family

ID=50819928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PT2014/000026 Ceased WO2015171002A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine

Country Status (29)

Country Link
US (1) US10226460B2 (en)
EP (2) EP3139926A1 (en)
JP (1) JP6400121B2 (en)
KR (1) KR102276281B1 (en)
CN (1) CN106413713B (en)
AU (1) AU2014393487B2 (en)
CA (1) CA2948595C (en)
DK (1) DK3831385T3 (en)
EC (1) ECSP16086196A (en)
ES (1) ES2988983T3 (en)
FI (1) FI3831385T3 (en)
HR (1) HRP20241165T1 (en)
HU (1) HUE068011T2 (en)
IL (1) IL248852B (en)
LT (1) LT3831385T (en)
MA (1) MA39450B2 (en)
MX (1) MX373227B (en)
NZ (1) NZ726127A (en)
PH (1) PH12016502235A1 (en)
PL (1) PL3831385T3 (en)
PT (1) PT3831385T (en)
RS (1) RS65918B1 (en)
RU (1) RU2706688C2 (en)
SA (1) SA516380258B1 (en)
SI (1) SI3831385T1 (en)
SM (1) SMT202400359T1 (en)
TN (1) TN2016000495A1 (en)
UA (1) UA118587C2 (en)
WO (1) WO2015171002A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831943A (en) * 2017-04-21 2020-02-21 社会医疗技术员技术股份公司 Process for preparing piperazine rings for synthesizing pyrazinocarbazole derivatives

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014393490B2 (en) * 2014-05-09 2020-01-02 Tecnimede Sociedade Tecnico-Medicinal S.A. (S)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX368735B (en) * 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (R) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE.
EP3392251A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053407A (en) * 1985-06-20 1991-10-01 Daiichi Pharmaceutical Co., Ltd. Optically active pyridobenzoxazine derivatives and anti-microbial use
WO2006048242A2 (en) * 2004-11-02 2006-05-11 Switch Biotech Ag Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
JP2012512165A (en) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド Treatment of multiple sclerosis using tetracyclic pyrazinoindole
US20150250808A1 (en) * 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
AU2014393490B2 (en) * 2014-05-09 2020-01-02 Tecnimede Sociedade Tecnico-Medicinal S.A. (S)-pirlindole or its pharmaceutically acceptable salts for use in medicine
DK3140265T3 (en) * 2014-05-09 2019-11-18 Tecnimede Sociedade Tecnico Medicinal S PROCEDURE FOR GETTING OPTICALLY ACTIVE PIRL INDOLENIENTS AND SALTS THEREOF
MX368735B (en) * 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (R) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053407A (en) * 1985-06-20 1991-10-01 Daiichi Pharmaceutical Co., Ltd. Optically active pyridobenzoxazine derivatives and anti-microbial use
WO2006048242A2 (en) * 2004-11-02 2006-05-11 Switch Biotech Ag Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US20080254106A1 (en) 2004-11-02 2008-10-16 Switch Biotech Ag Use Of Pirlindole For The Treatment Of Diseases Which Are Characterized By Proliferation Of T-Lymphocytes And/Or Hyperproliferation Of Keratinocytes In Particular Atopic Dermatitis And Psoriasis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Remington's The Science and Practice of Pharmacy"
A J REPTA ET AL: "Utilization of an enantiomer as a solution to a pharmaceutical problem: Application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 65, no. 2, February 1976 (1976-02-01), pages 238 - 242, XP055130861, DOI: 10.1002/jps.260065021 *
CHIRALITY, vol. 11, 1999, pages 261 - 266
MICHEL F. EICHELBAUM, BERNARD TESTA, ANDREW SOMOGYI (EDITORS): "Stereochemical Aspects of Drug Action and Disposition (Handbook of Experimental Pharmacology)", part 5 10 April 2003, SPRINGER, ISBN: 3540415939, article C.-H. GU,D. J. W. GRANT: "Physical Properties and Crystal Structures of Chiral Drugs", pages: 113 - 139, XP009179283 *
PASCAL DE TULLIO ET AL: "Effective resolution of racemic pirlindole at the preparative scale", CHIRALITY, vol. 11, no. 4, 29 March 1999 (1999-03-29), pages 261 - 266, XP055131009, ISSN: 0899-0042, DOI: 10.1002/(SICI)1520-636X(1999)11:4<261::AID-CHIR1>3.3.CO;2-J *
See also references of EP3139926A1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831943A (en) * 2017-04-21 2020-02-21 社会医疗技术员技术股份公司 Process for preparing piperazine rings for synthesizing pyrazinocarbazole derivatives
CN110831943B (en) * 2017-04-21 2022-05-03 社会医疗技术员技术股份公司 Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives

Also Published As

Publication number Publication date
MA39450A1 (en) 2017-08-31
CN106413713A (en) 2017-02-15
SI3831385T1 (en) 2024-11-29
CA2948595A1 (en) 2015-11-12
JP6400121B2 (en) 2018-10-03
EP3831385B1 (en) 2024-07-10
JP2017514882A (en) 2017-06-08
ECSP16086196A (en) 2017-02-24
EP3831385A1 (en) 2021-06-09
IL248852B (en) 2020-05-31
AU2014393487B2 (en) 2020-01-02
AU2014393487A1 (en) 2016-11-24
HUE068011T2 (en) 2024-12-28
RU2706688C2 (en) 2019-11-20
LT3831385T (en) 2024-09-10
RU2016148174A (en) 2018-06-14
US20170143710A1 (en) 2017-05-25
SMT202400359T1 (en) 2024-11-15
NZ726127A (en) 2019-03-29
DK3831385T3 (en) 2024-08-26
MA39450B2 (en) 2021-10-29
IL248852A0 (en) 2017-01-31
PL3831385T3 (en) 2024-10-14
ES2988983T3 (en) 2024-11-22
FI3831385T3 (en) 2024-09-04
RS65918B1 (en) 2024-10-31
UA118587C2 (en) 2019-02-11
KR20170002433A (en) 2017-01-06
EP3139926A1 (en) 2017-03-15
US10226460B2 (en) 2019-03-12
RU2016148174A3 (en) 2018-06-14
CN106413713B (en) 2020-07-14
PH12016502235A1 (en) 2017-01-09
MX2016014704A (en) 2017-05-23
KR102276281B1 (en) 2021-07-13
PT3831385T (en) 2024-09-24
TN2016000495A1 (en) 2018-04-04
CA2948595C (en) 2021-07-13
HRP20241165T1 (en) 2024-11-22
SA516380258B1 (en) 2019-11-04
MX373227B (en) 2020-04-21

Similar Documents

Publication Publication Date Title
CN101006081B (en) Nebivolol, pharmaceutically acceptable salt thereof, preparation method and pharmaceutical composition of nebivolol
WO2008067773A1 (en) New crystal types of febuxostat and their preparation methods
JP6731001B2 (en) Vortioxetine pyroglutamate
CA2948595C (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
WO2017153958A1 (en) Novel polymorphic forms and amorphous form of olaparib
CN111825547B (en) Salt of aryl propionic acid compound and pharmaceutical application thereof
KR20210128939A (en) Solid dispersion comprising niclosamide with increased oral bioavailability and preparation method thereof
CA2677649A1 (en) Bioavailable formulations of heterocyclic compounds
ES2277960T3 (en) FREE BASE OF AMLODIPINE.
US20050203115A1 (en) Narcotic-NSAID ion pairs
CN103724374B (en) A kind of benfotiamine compound and preparation method and the pharmaceutical composition containing this compound thereof
CA2618187C (en) Novel resinate complex of s-clopidogrel and production method thereof
CN111233877B (en) Galanthamine pamoate and preparation method thereof
JP2018048204A (en) Polymorphs of 4- [2-dimethylamino-1- (1-hydroxycyclohexyl) ethyl] phenyl 4-methylbenzoate hydrochloride, methods of making them and their use
WO2016097025A1 (en) Pharmaceutical composition comprising amorphous lenalidomide
KR102936624B1 (en) Amorphous solid dispersion comprising enzalutamide, and pharmaceutical formulation for oral administration comprising the same
AU2022239825B2 (en) Psilocybin analogs, salts, compositions, and methods of use
EP4580623A2 (en) Varenicline related compounds and methods for treating diseases and conditions including tobacco use disorder
WO2008032995A1 (en) Clopidogrel(+)-camphorsulfonate salt, method of preparing the same and a pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14726441

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2948595

Country of ref document: CA

Ref document number: 20167031370

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2016567531

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2016000569

Country of ref document: DZ

Ref document number: 15309981

Country of ref document: US

Ref document number: 248852

Country of ref document: IL

Ref document number: NC2016/0003924

Country of ref document: CO

Ref document number: 39450

Country of ref document: MA

Ref document number: 002199-2016

Country of ref document: PE

Ref document number: 12016502235

Country of ref document: PH

Ref document number: MX/A/2016/014704

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016025917

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014393487

Country of ref document: AU

Date of ref document: 20140509

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14339

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: A201611335

Country of ref document: UA

Ref document number: 2016/1149.1

Country of ref document: KZ

ENP Entry into the national phase

Ref document number: 2016148174

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014726441

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014726441

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112016025917

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161106